Inflation Reduction Act

Oct 9

Incubate Comments on Request for Information on Policy Solutions to Secure and Enhance Domestic Medical Supply Chains

Sep 20

Looking back and looking ahead: A momentous (and misguided) time for drug pricing policy

August was a momentous month for the life sciences ecosystem, and September looks to be just as significant. In this blog post, we want...

Incubate responds to Maximum Fair Prices for first 10 drugs selected for Medicare price controls

Incubate Coalition

Aug 15

Incubate responds to Maximum Fair Prices for first 10 drugs selected for Medicare price controls

WASHINGTON (August 15) -- Today, the Biden administration announced Maximum Fair Prices (MFPs) for the first 10 drugs selected for...

Incubate Submits Comments on Draft Guidance on the Medicare Drug Price Negotiation Program

Incubate Coalition

Jul 2

Incubate Submits Comments on Draft Guidance on the Medicare Drug Price Negotiation Program

Incubate Coalition

Jun 27

Incubate Life Sciences Open Letter

Incubate Launches Life Science Investment Tracker to Analyze Impact of the Inflation Reduction Act

Incubate Coalition

Jun 12

Incubate Launches Life Science Investment Tracker to Analyze Impact of the Inflation Reduction Act

WASHINGTON (June 13) -- Today, Incubate launched the Life Science Investment Tracker, a database monitoring changes in investment,...

Incubate Letter To Senate Judiciary Committee On “Ensuring Affordable & Accessible Medications: Examining Competition In The Prescription Drug Market” Hearing

Incubate Coalition

May 21

Incubate Letter To Senate Judiciary Committee On “Ensuring Affordable & Accessible Medications: Examining Competition In The Prescription Drug Market” Hearing

Incubate Submits Letter On HELP Committee Hearing

Incubate Coalition

Feb 7

Incubate Submits Letter On HELP Committee Hearing

Incubate is an international coalition of life science venture capitalists committed to educating policymakers on the role of venture...

Life Sciences Investors Applaud Bipartisan Bill To Eliminate Small-Molecule Penalty

Incubate Coalition

Feb 1

Life Sciences Investors Applaud Bipartisan Bill To Eliminate Small-Molecule Penalty

This bipartisan legislation would eliminate the small-molecule penalty by aligning the price-setting timeline for small and large...

Life Sciences Investors React To Biden Administration’s March-In Decision

Incubate Coalition

Dec 7, 2023

Life Sciences Investors React To Biden Administration’s March-In Decision

After a nine-month review, the Biden administration has reached the unprecedented and misguided conclusion that the 1980 Bayh-Dole Act...

What Is Up For Biopharmaceutical Policy In 2024?

Incubate Coalition

Nov 20, 2023

What Is Up For Biopharmaceutical Policy In 2024?

Incubate and DLA Piper invite you to join us on the morning of Sunday, January 7th, as part of JPM Week 2024. Attendees will gain an...

Mary R. Grealy On The Small Molecule Penalty, U.S. Dominance In Life Sciences, And More

Incubate Coalition

Oct 11, 2023

Mary R. Grealy On The Small Molecule Penalty, U.S. Dominance In Life Sciences, And More

Incubate Executive Director John Stanford sat down this week with Mary R. Grealy, CEO of the Healthcare Leadership Council, to discuss...

Incubate Releases Statement On Fitch Ratings’ Analysis Of Medicare Drug Price Negotiations

Incubate Coalition

Sep 25, 2023

Incubate Releases Statement On Fitch Ratings’ Analysis Of Medicare Drug Price Negotiations

Fitch Ratings recently released an analysis showing that Medicare's drug price negotiation program is expected to deter investments into...

Life Sciences Investors React To First 10 Drugs Selected For Government Price Controls

Incubate Coalition

Aug 28, 2023

Life Sciences Investors React To First 10 Drugs Selected For Government Price Controls

Executive Director John Stanford issued a statement in response. WASHINGTON, D.C. (August 29,2023) — Today, the Centers for Medicare &...

Incubate Submits Comment In Response To Draft Legislation To Reauthorize PAHPA

Incubate Coalition

Jul 9, 2023

Incubate Submits Comment In Response To Draft Legislation To Reauthorize PAHPA

Incubate recently submitted comment in response to the Senate HELP Committee’s draft legislation to reauthorize the Pandemic and...

Massachusetts Biotech Community Calls On Congress To Fix The Small Molecule Penalty

Incubate Coalition

May 21, 2023

Massachusetts Biotech Community Calls On Congress To Fix The Small Molecule Penalty

Given the tremendous focus of MA-based companies and investors, we had an opportunity to pen some thoughts which are shared in the...

Incubate Submits Comment To CMS Regarding Its Draft Guidance For The Medicare Drug Price Negotiation Program

Incubate Coalition

Apr 16, 2023

Incubate Submits Comment To CMS Regarding Its Draft Guidance For The Medicare Drug Price Negotiation Program

Incubate submitted our feedback to the Centers for Medicare & Medicaid Services regarding its draft guidance for the Medicare Drug Price...

The Inflation Reduction Act: Implications For Biopharma Companies And Patients

Incubate Coalition

Sep 22, 2022

The Inflation Reduction Act: Implications For Biopharma Companies And Patients

See our webinar, featuring DLA Piper, on the Inflation Reduction Act healthcare provisions. Incubate hosted a webinar today featuring ...

Incubate Statement On Amendment 5284 Of The Inflation Reduction Act

Incubate Coalition

Aug 5, 2022

Incubate Statement On Amendment 5284 Of The Inflation Reduction Act

Incubate issued the following statement in response to amendment 5284 of the Inflation Reduction Act: Incubate issued the following...

Incubate Statement On WTO Decision To Suspend Global IP Rights

Incubate Coalition

Jun 29, 2022

Incubate Statement On WTO Decision To Suspend Global IP Rights

The Incubate Coalition issued the following statement preceding the WTO TRIPS Council meeting (July 6-7) and following the World Trade...